Skip to main content


Table 1 Summary of studies on glucagon-like peptide-1 in hospitalized patients

From: Incretins in the ICU: is insulin on its way out?

  Deane and colleagues [1] Mussig and colleagues [14] Sokos and colleagues [15] Meier and colleagues [16]
Patient population ICU, mechanically ventilated Post CABG Pre and post CABG Post major surgery
Number of patients 7 20 20 8
Male/female 4/3 18/2 17/3 5/3
Diabetes mellitus No All 5/20 All
Nutrition Enteral feeding No parenteral feeding Allowed to eat Fasting
Intervention GLP-1 at 1.2 pmol/kg/minute GLP-1 at 3.6 pmol/kg/minute GLP-1 at 1.5 pmol/kg/minute GLP-1 at 1.2 pmol/kg/minute
Duration of intervention 4.5 hours 12 hours 12 hours before CABG to 48 hours after CABG 8 hours
Control group Placebo (albumin) Insulin Placebo (saline) Placebo
Results Significantly decreased AUC for glucose Glycemic control comparable with insulin-treated group Significantly decreased AUC for glucose Normoglycemia
Side effects None None One episode of hypoglycemia None
  1. AUC, area under the curve; CABG, coronary artery bypass grafting; GLP-1, glucagon-like peptide-1; ICU, intensive care unit.